Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two Admit Collusion On UK Nortriptyline

Executive Summary

Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.

You may also be interested in...

UK’s CMA Fines Four On Nortriptyline

Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.

Four Accused By UK's CMA On Nortriptyline

King Pharmaceuticals and Auden Mckenzie have been accused by the UK’s competition regulator of sharing out the supply of nortriptyline 10mg and 25mg tablets, in a case that also implicates Alissa and Lexon for exchanging commercially-sensitive information as part of an effort to drive up prices.

Who’s Hired? Four Firms Focus On Finance

A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts